Literature DB >> 30320103

Atypical Presentation of Bilateral Retinoblastoma with Floaters and Sub-Internal Limiting Membrane Seeds in an 11-Year-Old Asian Indian Male.

Pukhraj Rishi1, Subramanian Krishnakumar2, Jyotirmay Biswas2, Sridevi Nair1.   

Abstract

PURPOSE: To report bilateral retinoblastoma in an 11-year-old child presenting with floaters and sub-internal limiting membrane (sub-ILM) seeds.
METHOD: An 11-year-old child presented with floaters of 4 months' duration. Examination revealed circumscribed, whitish, subhyaloid, floccular nodules in the juxtapapillary region of both eyes. No solid tumor was seen. Swept-source optical coherence tomography revealed moderately reflective echoes in the sub-ILM space. Vitreous aspiration of sub-ILM deposits and cytopathological examination revealed retinoblastoma. Intravitreal melphalan (20 μg/0.02 mL) was followed by 6 monthly cycles of high-dose systemic chemotherapy (vincristine, etoposide, carboplatin). Metastatic workup and genetic testing for RB1 mutational screening were negative. Ocular lesions resolved after 13 weeks of treatment. Brain metastases developed after 20 weeks and were treated with radiation. Bilateral vitreous seeds recurred at 44 weeks and were treated with intravitreal chemotherapy (melphalan 20 μg/0.02 mL and topotecan 20 μg/0.02 mL). There was no extra-ocular spread from sclerotomy sites.
RESULTS: Retinoblastoma and brain metastases resolved with multimodal treatment without recurrence at 59 weeks of follow-up.
CONCLUSION: Atypical manifestation of retinoblastoma can be seen in older children presenting with "floaters" and bilateral deposits of sub-ILM seeds, without solid tumor.

Entities:  

Keywords:  Atypical manifestation of retinoblastoma; Retinoblastoma

Year:  2018        PMID: 30320103      PMCID: PMC6167686          DOI: 10.1159/000486341

Source DB:  PubMed          Journal:  Ocul Oncol Pathol        ISSN: 2296-4657


  7 in total

Review 1.  Detection of structural DNA variation from next generation sequencing data: a review of informatic approaches.

Authors:  Haley J Abel; Eric J Duncavage
Journal:  Cancer Genet       Date:  2013-11-20

2.  Unusual subretinal seeding of retinoblastoma.

Authors:  T G Farkas; F A Mausolf
Journal:  Am J Ophthalmol       Date:  1968-04       Impact factor: 5.258

3.  Metastatic retinoblastoma clinical features, treatment, and prognosis.

Authors:  Kaan Gündüz; Orkun Müftüoglu; Ilhan Günalp; Emel Unal; Nurdan Taçyildiz
Journal:  Ophthalmology       Date:  2006-07-07       Impact factor: 12.079

4.  Factors predictive of recurrence of retinal tumors, vitreous seeds, and subretinal seeds following chemoreduction for retinoblastoma.

Authors:  Carol L Shields; Santosh G Honavar; Jerry A Shields; Hakan Demirci; Anna T Meadows; Thomas John Naduvilath
Journal:  Arch Ophthalmol       Date:  2002-04

5.  Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies.

Authors:  Diane E Rushlow; Berber M Mol; Jennifer Y Kennett; Stephanie Yee; Sanja Pajovic; Brigitte L Thériault; Nadia L Prigoda-Lee; Clarellen Spencer; Helen Dimaras; Timothy W Corson; Renée Pang; Christine Massey; Roseline Godbout; Zhe Jiang; Eldad Zacksenhaus; Katherine Paton; Annette C Moll; Claude Houdayer; Anthony Raizis; William Halliday; Wan L Lam; Paul C Boutros; Dietmar Lohmann; Josephine C Dorsman; Brenda L Gallie
Journal:  Lancet Oncol       Date:  2013-03-13       Impact factor: 41.316

6.  Treatment of metastatic retinoblastoma.

Authors:  Carlos Rodriguez-Galindo; Matthew W Wilson; Barrett G Haik; Mindy J Lipson; Alvida Cain; Thomas E Merchant; Sue Kaste; Charles B Pratt
Journal:  Ophthalmology       Date:  2003-06       Impact factor: 12.079

7.  Screening for large rearrangements of the RB1 gene in Iranian patients with retinoblastoma using multiplex ligation-dependent probe amplification.

Authors:  Ali Ahani; Mohammad Taghi Akbari; Kioomars Saliminejad; Babak Behnam; Mohammad Mehdi Akhondi; Parvaneh Vosoogh; Farriba Ghassemi; Masood Naseripour; Gholamreza Bahoush; Hamid Reza Khorram Khorshid
Journal:  Mol Vis       Date:  2013-02-22       Impact factor: 2.367

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.